Oral cavity carcinoma
diseaseOn this page
Also known as carcinoma of mouthcarcinoma of oral cavitycarcinoma of the oral cavitymouth carcinomaoral cavity cancer
Summary
Oral cavity carcinoma (MONDO:0044925) is a cancer (an umbrella term covering 9 Mondo subtypes) and 57 clinical trials. Top therapeutic interventions include celecoxib, dacomitinib anhydrous, and metformin. A subtype of oral cavity cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 9 Mondo subtypes
- Clinical trials: 57
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | oral cavity carcinoma |
| Mondo ID | MONDO:0044925 |
| NCIT | C8990 |
| UMLS | C0151546 |
| MedGen | 57468 |
| GARD | 0027982 |
| Anatomy (UBERON) | UBERON:0000167 |
| Is cancer (heuristic) | yes |
Also known as: carcinoma of mouth · carcinoma of oral cavity · carcinoma of the oral cavity · mouth carcinoma · oral cavity cancer · oral cavity carcinoma
Disease family
This is a subtype of oral cavity cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › oral cavity cancer › oral cavity carcinoma
Related subtypes (10): soft palate cancer, tongue cancer, cheek mucosa cancer, salivary gland cancer, retromolar area cancer, hard palate cancer, vestibule of mouth cancer, gingival cancer, lip cancer, oral rhabdomyosarcoma
Subtypes (9): oral cavity carcinoma in situ, salivary gland carcinoma, oral cavity squamous cell carcinoma, carcinoma of soft palate, carcinoma of lip, carcinoma of hard palate, oral cavity mucoepidermoid carcinoma, tongue carcinoma, intraoral basal cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 57.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 29 |
| PHASE2 | 17 |
| PHASE1 | 5 |
| PHASE3 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05429099 | PHASE2/PHASE3 | RECRUITING | Mandibular Reconstruction Preplanning (ViPMR) |
| NCT06798922 | PHASE3 | RECRUITING | Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers |
| NCT00359645 | PHASE3 | COMPLETED | Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population |
| NCT00934739 | PHASE2/PHASE3 | TERMINATED | A Study of High-Risk Oral Cavity Cancer |
| NCT05369234 | PHASE3 | COMPLETED | Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis |
| NCT02581137 | PHASE2 | ACTIVE_NOT_RECRUITING | Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion |
| NCT02834013 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
| NCT04870762 | PHASE2 | RECRUITING | Customized 3D Printed Oral Stents During Head and Neck Radiotherapy |
| NCT05075980 | PHASE2 | ACTIVE_NOT_RECRUITING | Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study |
| NCT06728631 | PHASE2 | ACTIVE_NOT_RECRUITING | Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL |
| NCT06876038 | PHASE2 | NOT_YET_RECRUITING | Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions |
| NCT06997068 | PHASE2 | RECRUITING | Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population |
| NCT07063212 | PHASE2 | RECRUITING | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) |
| NCT07209189 | PHASE2 | RECRUITING | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) |
| NCT00780312 | PHASE2 | COMPLETED | Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer |
| NCT01116843 | PHASE1/PHASE2 | COMPLETED | Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment |
| NCT01695122 | PHASE2 | COMPLETED | Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma |
| NCT02882282 | PHASE2 | COMPLETED | Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia |
| NCT03082534 | PHASE2 | COMPLETED | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
| NCT03096808 | PHASE2 | COMPLETED | Adaptive Radiotherapy for Head and Neck Cancer |
| NCT04065737 | PHASE2 | UNKNOWN | Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization |
| NCT04162873 | PHASE2 | TERMINATED | Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer |
| NCT04330781 | PHASE2 | COMPLETED | Radiotherapy of Head and Neck Cancer Using an Intraoral Stent |
| NCT06736379 | PHASE1 | RECRUITING | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer |
| NCT01140178 | PHASE1 | COMPLETED | A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx |
| NCT02586207 | PHASE1 | COMPLETED | Pembrolizumab in Combination With CRT for LA-SCCHN |
| NCT04892875 | PHASE1 | WITHDRAWN | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers |
| NCT05536037 | PHASE1 | TERMINATED | Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions |
| NCT00867464 | Not specified | ACTIVE_NOT_RECRUITING | Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls |
| NCT01958762 | Not specified | RECRUITING | Screening for Cancers in the Oral CAvity |
| NCT02012699 | Not specified | RECRUITING | Integrated Cancer Repository for Cancer Research |
| NCT04809324 | Not specified | RECRUITING | Gross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers |
| NCT05337631 | Not specified | RECRUITING | Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy |
| NCT05375266 | Not specified | RECRUITING | Immune Biomarker Study for Head and Neck Cancer |
| NCT05740033 | Not specified | RECRUITING | Radial Forearm Donor Site Closure |
| NCT05757817 | Not specified | RECRUITING | Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae |
| NCT05793151 | Not specified | RECRUITING | Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy |
| NCT05798780 | Not specified | ACTIVE_NOT_RECRUITING | The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors |
| NCT05973656 | Not specified | RECRUITING | Role of Acetaldehyde in the Development of Oral Cancer |
| NCT06407570 | Not specified | NOT_YET_RECRUITING | Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CELECOXIB | 4 | 3 |
| DACOMITINIB ANHYDROUS | 4 | 1 |
| METFORMIN | 4 | 1 |
| NAPROXEN SODIUM | 4 | 1 |
| SACITUZUMAB GOVITECAN | 4 | 1 |
| SUCRALFATE | 4 | 1 |
| THALIDOMIDE | 4 | 1 |
| VALPROIC ACID | 4 | 1 |
| SINTILIMAB | 3 | 1 |
| ZIMBERELIMAB | 3 | 1 |
| ETRUMADENANT | 2 | 1 |
| HPPH | 2 | 1 |
| CHEMBL426123 | 0 | 1 |